Vividion Therapeutics, a San Diego, CA-based biotechnology company with a platform to discover small molecule therapeutics against biologically compelling but previously intractable targets, closed an $82M Series B financing.
The round was led by Nextech Invest, with participation from additional new investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital, Altitude Life Science Ventures, and Alexandria Venture Investments and existing investors ARCH Venture Partners, Versant Ventures, Cardinal Partners and Celgene Corporation. In conjunction with the funding, Jakob Loven, Ph.D., Partner at Nextech Invest, will join the Vividion Board of Directors.
The company intends to use the funds to continue to expand operations to continue to advance its research efforts.
Led by Dr. Diego Miralles, Chief Executive Officer, Vividion Therapeutics has pioneered an approach based on seminal work from the labs of Professors Benjamin Cravatt, Phil Baran, and Jin-Quan Yu at The Scripps Research Institute in La Jolla, CA, that enables screening of small molecules against every protein in native biological systems. Its platform identifies highly selective binders to previously intractable targets, agnostic to protein class and function.
These can be developed into drugs utilizing a range of approaches, including direct and allosteric modulation of protein function, and targeted protein degradation. The company’s immediate focus is in oncology and immunology.